Solid Biosciences Secures $240M Funding, Targets April Phase 3 Duchenne Dosing
Solid Biosciences reported $187.9 million in cash and completed a $240 million private placement, extending runway into H1 2028. The company dosed 41 participants in Phase 1/2 INSPIRE DUCHENNE with robust microdystrophin expression and plans Phase 3 IMPACT DUCHENNE dosing in April.
1. Financial Results and Cash Position
As of December 31, 2025, Solid held $187.9 million in cash, cash equivalents, and securities, up from $148.9 million a year earlier. In March 2026, the company raised $240 million through a private placement, extending its operational runway into the first half of 2028.
2. INSPIRE DUCHENNE Interim Data
In the Phase 1/2 INSPIRE trial, 41 Duchenne participants have been dosed, showing robust microdystrophin expression, restoration of beta-sarcoglycan and nNOS, improvement in muscle biomarkers, and stabilized left ventricular ejection fraction under a steroid-only immunomodulation regimen.
3. Phase 3 IMPACT DUCHENNE Plans and FDA Meetings
Participant screening for the randomized, double-blind, placebo-controlled Phase 3 IMPACT DUCHENNE trial is underway, with first dosing anticipated in April 2026. The company expects additional FDA engagements in H1 2026 to explore an accelerated approval pathway for SGT-003.
4. Pipeline Expansion and Partnership Activity
Solid dosed its first participant in the Phase 1b FALCON trial for SGT-212 in Friedreich’s ataxia and activated sites for the Phase 1b ARTEMIS trial of SGT-501, with dosing expected in Q2 2026. The POLARIS-101 capsid platform has been licensed in over 50 agreements.